FORT LEE, N.J., Sept. 20, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, announced today that Adrian Adams has been appointed Company Chairman and Chief Executive Officer (CEO) effective immediately. In addition, Andrew I. Koven joins the Neurologix executive team as the Company's President and Chief Administrative Officer. Both Messrs. Adams and Koven will also immediately join the Company's Board of Directors, with Mr. Adams assuming the role of its Chairman.
Mr. Adams brings over 30 years of experience in pharmaceutical executive leadership with a record of successfully building organizations, delivering successful results against short, medium and long-term goals and creating shareholder value. In his role as Chairman and CEO, Mr. Adams will work toward strengthening the Company's research and development, operations and commercial infrastructures in support of Neurologix's lead compound, NLX-P101, which has demonstrated positive results to date in the treatment of Parkinson's disease.
"I am excited to join Neurologix, a company with innovative and pioneering science at its core. Along with new President Andrew Koven and the current quality executive team, I look forward to assembling over time a strong and peak-performing organization that will build upon the Company's legacy of groundbreaking research and development of gene therapy treatments for Parkinson's disease and other specialty neurological conditions, with the goal of bringing important new treatments to physicians and their patients," said Mr. Adams.
Most recently, Mr. Adams served as President and CEO of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co. Inc. for approxim
|SOURCE Neurologix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved